Hook and thesis
TG Therapeutics is a classic asymmetric trade right now: accelerating BRIUMVI sales have translated into tangible revenue growth and improving profitability, while a compact share base and the prospect of selective buybacks provide a floor under the stock. The market is already rewarding that progress — TGTX sits at $33.20 today and the technicals show momentum — but valuation remains reasonable versus near-term earnings, making a long trade with a well-defined stop worthwhile.
Thesis in short: Buy at $33.20 with a $46.48 target and $29.00 stop. BRIUMVI sales growth (Q1 U.S. net sales $119.7M; full-year 2025 guidance lifted toward $585M) supports upside; the company's profitability (reported EPS $2.80 and P/E ~11.25) limits downside, and even modest buybacks would materially reduce float and compress available shares to short sellers.
Why the market should care - the business and the fundamental driver
TG Therapeutics is focused on B-cell malignancies and autoimmune diseases, with its commercial engine centered on BRIUMVI for multiple sclerosis. The commercialization pathway for BRIUMVI is the fundamental driver here: recent quarterly reporting showed meaningful U.S. net sales momentum and management raised full-year revenue expectations. That trajectory converts an earlier growth story into a growth-to-earnings story.
Concrete numbers that matter: Q1 2025 U.S. net sales for BRIUMVI were $119.7 million (reported 05/05/2025) and the company subsequently raised full-year revenue guidance toward $585 million (announcement 08/04/2025), after Q2 revenue grew 91%. On the profitability side, reported earnings per share are $2.80 and the stock trades at a P/E near 11.25 — cheap for a company moving from product ramp toward sustainable profits. Market capitalization is roughly $5.30 billion and enterprise value about $5.20 billion, so the market is valuing the company like a mid-cap commercial-stage biotech with a profitable quarter in sight.
How the pieces fit together
Rising sales reduce binary regulatory risk and increase optionality for additional indications and dosing formats (management has noted subcutaneous BRIUMVI development). That pipeline optionality is pure upside; the immediate driver is commercial execution. The company has shown the ability to turn BRIUMVI into a sizable revenue stream quickly, and the market is rewarding it with higher multiples that are still reasonable relative to earnings — again, P/E ~11 is modest compared with many commercial biotech peers where revenue growth is lower but multiples are higher.
Technical and market structure context
Technically, TGTX is in bullish momentum: the current price of $33.20 sits above the 10-, 20- and 50-day SMAs (10-day ~ $31.14, 20-day ~ $30.03, 50-day ~ $29.87), the RSI is in bullish territory around 65.5 and MACD shows a positive histogram. Volume has been supportive — today's volume ran higher than the recent averages. Short interest remains material: recent settlement figures show roughly 28 million shares short with a days-to-cover in the mid-teens. That combination can amplify upside on positive prints and also make selective repurchases by the company meaningful in reducing floating supply.
Valuation framing
At a market cap near $5.30 billion and enterprise value near $5.20 billion, TG trades at about 11x reported earnings (EPS $2.80) and ~8.16x price-to-sales. Those are not nose-bleed multiples for a company that is already generating hundreds of millions in revenue and turning a profit. The price-to-book of ~7.55 is elevated, but the high ROE (~69%) demonstrates that capital is being deployed efficiently. On a qualitative basis, TG looks like a growth company that has crossed into profitability — a combination that typically warrants a P/E premium versus pure-growth biotechs. The current multiple appears to leave room for upside if the BRIUMVI ramp continues toward the mid-single-digit hundreds of millions to >$500M annual revenue mark the company guided toward in 2025.
Catalysts to watch (2-5)
- Quarterly revenue and BRIUMVI sales cadence - next quarterly report will be a key check on whether the $585M full-year guide is staying intact.
- Updates on subcutaneous BRIUMVI and any label expansion efforts - positive clinical or regulatory news lifts the long-term multiple.
- Commercial activity and awareness campaigns (e.g., the Christina Applegate collaboration launched 02/08/2026) that broaden patient reach and prescribing momentum.
- A formal announcement of a share repurchase program or evidence of sustained repurchases - even modest buybacks against a float of ~148M shares reduce supply and help stabilize price.
Trade plan (actionable)
Rationale for the horizon: this is not a short-term momentum scalp. The case relies on continued commercial execution, potential regulatory/pathway updates around subcutaneous dosing, and the time it takes for buybacks (if announced) and institutional re-rating to impact price. That timeline fits a 180 trading-day holding period.
Risks and counterarguments
- Commercial execution risk: BRIUMVI sales could plateau or miss expectations. The bull case depends on continued sequential strength following Q1 and Q2 2025 prints.
- Competition and reimbursement: MS is a competitive category; pricing pressure, payer pushback or new competitor wins could slow adoption.
- Balance sheet and cash flow: Free cash flow was slightly negative in recent reporting (-$24.99M); if the company needs to divert cash to operations or R&D, the pace of buybacks could be limited.
- Short interest and volatility: High short interest and elevated days-to-cover can create whipsaw price action. While that amplifies upside, it can also produce steep intraday reversals that could trigger stops.
- Regulatory or safety surprises: Any unexpected safety signal or label restriction would materially hurt adoption and share price.
Counterargument to the thesis
A skeptical view is straightforward: the company may have already priced in the best near-term outcomes. If BRIUMVI sales slow, or if payers begin to push back on access, the stock could re-rate lower quickly. Additionally, negative free cash flow raises the possibility that management prioritizes pipeline investment over buybacks, meaning the downside protection from repurchases may be overstated. In that scenario, the stock could revisit the low-$20s support band observed last year.
Why I still prefer the long here
Despite those counterarguments, the combination of accelerating sales, actual profitability (EPS $2.80), a reasonable P/E (~11.25), and a float/shares profile that makes even modest buybacks meaningful supports a tactical long. The technical backdrop is constructive and volume shows investor willingness to participate. The trade is sized to risk the stop at $29.00 — a level that respects the 50-day moving average and limits downside if commercial momentum weakens.
Conclusion and what would change my mind
I am inclined to buy TGTX at $33.20 with a target of $46.48 and a stop at $29.00, horizon ~180 trading days. The trade is a mix of fundamental conviction (BRIUMVI sales ramp + profitability) and market structure (short interest + manageable float) that can amplify returns. I will change my stance if: 1) next-quarter revenue or BRIUMVI sales meaningfully miss the raised guidance, 2) management reverses course on capital allocation and commits cash primarily to R&D with no buyback intention, or 3) a substantive negative safety/regulatory development emerges. Conversely, an announced repurchase program, better-than-expected sales cadence or a clear path for label expansion would make me more aggressively bullish and justify raising the target and trimming the stop.
Trade idea summary: Enter long at $33.20, stop $29.00, target $46.48. Horizon: long term (180 trading days). Risk level: medium.